Market Overview - The Shanghai Composite Index closed at 3771.10 points, above the annual line, with a change of 0.13% [1] - The total trading volume of A-shares reached 24603.35 billion yuan [1] Stocks Breaking Annual Line - A total of 28 A-shares have surpassed the annual line today, with notable stocks including: - Meihua Medical (301363) with a deviation rate of 14.81% and a daily increase of 18.00% [1] - Meirui New Materials (300848) with a deviation rate of 4.67% and a daily increase of 5.49% [1] - Kangle Health (833575) with a deviation rate of 4.29% and a daily increase of 4.40% [1] Stocks with Smaller Deviation Rates - Stocks that have just crossed the annual line with smaller deviation rates include: - Guotou Power (600886) with a deviation rate of 0.01% and a daily increase of 1.30% [2] - Shanghai Pharmaceuticals (601607) with a deviation rate of 0.08% and a daily increase of 0.95% [2] - *ST Jinglun (600355) with a deviation rate of 0.20% and a daily increase of 0.86% [2]

Market Overview - The Shanghai Composite Index is at 3781.13 points, above the annual line, with a change of 0.40% [1] - The total trading volume of A-shares is 1,193.158 billion yuan [1] Stocks Breaking Annual Line - A total of 31 A-shares have surpassed the annual line today, with notable stocks including Meihua Medical, *ST Aowei, and Pianzaihuang, showing divergence rates of 14.13%, 2.94%, and 2.77% respectively [1] - Stocks with smaller divergence rates that have just crossed the annual line include China Wuyi, Huilun Crystal, and Zhuoshengwei [1] Top Stocks by Divergence Rate - Meihua Medical (301363) has a significant increase of 17.30% with a turnover rate of 23.04% and a divergence rate of 14.13% [1] - *ST Aowei (002231) increased by 3.12% with a turnover rate of 7.79% and a divergence rate of 2.94% [1] - Pianzaihuang (600436) rose by 3.70% with a turnover rate of 1.03% and a divergence rate of 2.77% [1] Additional Notable Stocks - Tongrentang (600085) increased by 1.93% with a divergence rate of 1.77% [1] - Maire Medical (300760) rose by 3.40% with a divergence rate of 1.53% [1] - Other stocks with minor divergence rates include Aima Technology (603529) and China Railway Construction (601186) with divergence rates of 1.06% and 0.96% respectively [1]

Group 1 - The core viewpoint of the article highlights the decline in the production of traditional Chinese medicine (TCM) in China, with a projected decrease in output and significant year-on-year reductions [1][3] - According to data from the National Bureau of Statistics, the production of TCM in China is expected to be 156,000 tons by June 2025, representing a year-on-year decrease of 6.6% [1] - In the first half of 2025, the cumulative production of TCM in China reached 875,000 tons, showing a cumulative decline of 13% [1] Group 2 - The article lists several publicly listed companies in the TCM sector, including Yunnan Baiyao, Tongrentang, and others, indicating the key players in the industry [1] - The report referenced is the "2025-2031 China Traditional Chinese Medicine Industry Development Situation Analysis and Industry Prospect Planning Report" published by Zhiyan Consulting, which provides insights into the future of the TCM industry [1][2]

此外，董事会于2025年8月18日决议委任张春友先生为董事会的战略与规划委员会委员，并于同日生 效。 同仁堂（600085）科技(01666)发布公告，经股东于股东特别大会批准后，董事会仅此宣布，自2025年8 月18日起，张春友先生及温凯婷女士获委任为公司第九届董事会的执行董事。邸淑兵先生、陈加富先生 及冯智梅女士辞任非执行董事亦于同日起生效。 ...

此外，董事会于2025年8月18日决议委任张春友先生为董事会的战略与规划委员会委员，并于同日生 效。 智通财经APP讯，同仁堂科技(01666)发布公告，经股东于股东特别大会批准后，董事会仅此宣布，自 2025年8月18日起，张春友先生及温凯婷女士获委任为公司第九届董事会的执行董事。邸淑兵先生、陈 加富先生及冯智梅女士辞任非执行董事亦于同日起生效。 ...

Core Viewpoint - Tong Ren Tang Technologies (01666.HK) announced the appointment of Zhang Chunyou and Wen Kaiti as executive directors of the company's ninth board of directors, effective from August 18, 2025 [1] Group 1 - Zhang Chunyou has been appointed as a member of the board's Strategy and Planning Committee, effective on the same date [1]

Industry Overview - The number of registered companies in China's Ejiao industry has shown a growth trend, with over 600 companies registered as of June 2025, and nearly 200 new companies added between 2016 and 2020 [1][3] - The production of Ejiao blocks in China is projected to increase, with an estimated production of 4,379 tons in 2024 [3] Supply Situation - The sales-to-production ratio of Dong'e Ejiao has been declining over the past three years, dropping from 100.9% in 2022 to 97.9% in 2024, indicating increased inventory pressure [5] Demand Scale - The market size of the Ejiao industry in China is expected to reach approximately 29.1 billion yuan in 2024, driven by rising disposable income and increased health awareness among consumers [7] Price Trends - The prices of Ejiao products from major brands like Dong'e Ejiao and Fupai Ejiao have remained stable, with Dong'e Ejiao priced at 2,700 yuan per kilogram and Fupai Ejiao at approximately 1,260 yuan per kilogram [9]

Group 1 - The core viewpoint of the news is the strong performance of the Chinese traditional medicine sector, highlighted by the rise of the Zhongzheng Traditional Chinese Medicine Index and its constituent stocks following a new policy from the Liaoning Provincial Medical Insurance Bureau [1][2] - The Zhongzheng Traditional Chinese Medicine Index (930641) increased by 1.62%, with notable gains from Tian Shili (600535) up 8.03%, Xin Tian Pharmaceutical (002873) up 7.01%, and Da Ren Tang (600329) up 6.07% [1] - The new policy includes the integration and regulation of three types of medical service pricing, specifically incorporating 39 medical service items, including "traditional Chinese medicine plaster," into the provincial basic medical insurance and work injury insurance fund payment scope, effective from August 20, 2025 [1] Group 2 - Dongwu Securities indicates that the innovative drug industry in China has reached a turning point, with significant advancements in both policy and research and development [2] - The policy framework, including the "Full Chain Support for Innovative Drug Development Implementation Plan," provides support across payment, approval, and financing sectors, facilitating industry growth [2] - As of Q1 2025, the coverage of First-in-Class (FIC) innovative drugs in China reached 40%, with a notable presence of dual-antibody pipelines at the 2025 ASCO conference, indicating global academic recognition [2] Group 3 - As of July 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.58% of the index, with key players including Yunnan Baiyao (000538) and Pian Zai Huang (600436) [3]

同仁堂（600085）科技(01666)发布公告，于2025年8月15日召开的公司职工代表大会上，朱东生先生获 选举为公司第九届董事会之职工董事，任期自章程修正案经股东特别大会批准通过之日起生效，至本届 董事会任期结束终止，并在其任期届满时可以连选连任。 ...

智通财经APP讯，同仁堂科技(01666)发布公告，于2025年8月15日召开的公司职工代表大会上，朱东生 先生获选举为公司第九届董事会之职工董事，任期自章程修正案经股东特别大会批准通过之日起生效， 至本届董事会任期结束终止，并在其任期届满时可以连选连任。 ...